Treatment of patients with widespread peritonitis requires health institutions of considerable financial outlay, with the budget of a multidisciplinary hospital antibacterial drugs accounts for up to 40% of the cost. Definition of the effectiveness empirical antimicrobial therapy in patients with widespread peritonitis is an important factor in successful treatment.
On the basis of our data on the identification and determination of susceptibility to antibacterial medicines microflora of peritoneal exudate in patients with widespread peritonitis developed schema of empirical antibiotic therapy, taking into account the levels of integrity of the gastrointestinal tract. Solved pharmacoeconomic analysis of antimicrobial therapy in 319 patients with widespread peritonitis. Economic evaluation of the effectiveness of the treatment was carried out on the basis of the «cost-effectiveness» and «minimize cost». The calculation is made according to the formula, using as units of the efficiency coefficient of avoided complications and deaths averted.
Antibacterial therapy costs in total costs of medicines amounted to 55,1% in traditional methods of bacteriological research and treatment, 63,3% when applying the developed test-systems for identification and microflora sensitivity to antibacterial medicines, 60,7% – if you use schema developed empirical antibiotic therapy. Based on an analysis of cost-effectiveness, it was found that savings when using schemas empirical antibiotic therapy in the treatment of one patient was $579,2 compared to traditional treatment, total savings $45756,8.
Thus, application schema developed empirical antimicrobial therapy, taking into account the levels of integrity to the gastrointestinal tract in patients with widespread peritonitis can significantly reduce the cost of treatment and have high economic efficiency.

1. Борисов, Р. Н. Оценка эффективности лечения больных с распространенным гнойным перитонитом / Р. Н. Борисов, В. А. Белобородов // Сибирский медицинский журнал. – 2011. – № 1. – С. 20–22.

2. Воробьев, П. А. Клинико-экономический анализ / П. А. Воробьев [и др.]; под общ. ред. П. А. Воробьева. – М.: Ньюдиамед, 2008. – 778 с.

3. Ефименко, Н. А. Инфекции в хирургии. Фармакотерапия и профилактика: Монография / Н. А. Ефименко, И. А. Гучев, С. В. Сидоренко. – Смоленск. – 2004. – 296 с.

4. Инструкция по применению «Порядок проведения клинико-экономических исследований»: утв. М-вом здравоохранения Респ. Беларусь 03.10.08. – Минск: ГУ «РНПЦ медицинских технологий, информатизации, управления и экономики здравоохранения», 2008. – 39 с.

5. Макушкин, Р. З. Клинико-фармакологический анализ стоимости лечения распространенного гнойного перитонита / Р. З. Макушкин [и др.] // Медицинский вестник Северного Кавказа. – 2011. – № 4. – С. 53–55.

6. Малков, И. С. Оценка эффективности лечения больных с распространенным перитонитом. / И. С. Малков, Э. К. Салахов // Практическая медицина. – 2010. – № 1. – С. 82–86.

7. Яковлев, С. В. Антимикробная профилактика перитонита / С. В. Яковлев [и др.] // Инфекции в хирургии. – 2007. – Т. 5, № 4. – С. 10–14.

8. Andersson, D. I. Antibiotic resistance and its cost: is it possible to reverse resistance? / D. I. Andersson, D. Hughes // Nat. Rev. Microbiol. – 2010. – № 8. – P. 260–271.

9. Augustin, P. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis /P. Augustin [et al] // Crit. Care. – 2010. – Vol.14:R20 http://ccforum.com/content/14/1/R20.

10. Cattan, P. Cost of care for inpatients with communityacquired intra-abdominal infections / P. Cattan [et al] // Eur. J. Clin. Microbiol. Infect. Dis. – 2002. – Vol. 21. – P. 787–793.

11. Dalfino, L. Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy: a retrospective study / L. Dalfino [et al] //World J. of Em. Surg. – 2014. – Vol. 9. – P. 39. http://www.wjes.org/content/9/1/39.

12. De Simone, В. Benefits of WSES guidelines application for the management of intra-abdominal infections / B. De Simone [et al] //World J. of Em. Surg. – 2015. – Vol. 10. – P. 18 DOI 10.1186/s13017-015-0013-x.

13. Eckmann, С. Antimicrobial treatment of “complicated” intra-abdominal infections and the new guidelines – A commentary and an alternative european approach according to clinical definitions / C. Eckmann [et al] // Eur. J. Med. Res. – 2011. – Vol. 16. – P. 115–126.

14. Giske, C. G. Clinical and economic impact of common multidrug-resistant gram-negative bacilli / C. G. Giske[et al]// Antimicrob.Agents Chemother. – 2008. – Vol. 52. – P. 813–821.

15. Roberts, R. R. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods / R. R. Roberts [et al] // Med. Care – 2010. – Vol. 48. – P. 1026–1035.